These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23206221)

  • 1. Sub-lethal concentrations of antibiotics increase mutation frequency in the cystic fibrosis pathogen Pseudomonas aeruginosa.
    Nair CG; Chao C; Ryall B; Williams HD
    Lett Appl Microbiol; 2013 Feb; 56(2):149-54. PubMed ID: 23206221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.
    Millar BC; McCaughan J; Rendall JC; Downey DG; Moore JE
    J Clin Pharm Ther; 2018 Feb; 43(1):92-100. PubMed ID: 29293275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis Patients.
    Martin LW; Robson CL; Watts AM; Gray AR; Wainwright CE; Bell SC; Ramsay KA; Kidd TJ; Reid DW; Brockway B; Lamont IL
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30201819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occurrence of antipseudomonal beta-lactams and aminoglycosides resistance in Pseudomonas aeruginosa during therapy.
    Pagani L; Scarabelli M; Cereda PM; Debiaggi M
    Microbiologica; 1987 Jan; 10(1):103-10. PubMed ID: 3106759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Epidemiology of Mutations in Antimicrobial Resistance Loci of Pseudomonas aeruginosa Isolates from Airways of Cystic Fibrosis Patients.
    Greipel L; Fischer S; Klockgether J; Dorda M; Mielke S; Wiehlmann L; Cramer N; Tümmler B
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6726-6734. PubMed ID: 27572404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diversity of β-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study.
    Llanes C; Pourcel C; Richardot C; Plésiat P; Fichant G; Cavallo JD; Mérens A;
    J Antimicrob Chemother; 2013 Aug; 68(8):1763-71. PubMed ID: 23629014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
    Hocquet D; Berthelot P; Roussel-Delvallez M; Favre R; Jeannot K; Bajolet O; Marty N; Grattard F; Mariani-Kurkdjian P; Bingen E; Husson MO; Couetdic G; Plésiat P
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3531-6. PubMed ID: 17682106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing Incidence of Multidrug Resistance Among Cystic Fibrosis Respiratory Bacterial Isolates.
    Rutter WC; Burgess DR; Burgess DS
    Microb Drug Resist; 2017 Jan; 23(1):51-55. PubMed ID: 27326758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vitro effect of various antibiotics: beta lactams, aminoglycosides and fluoroquinolones alone and in combination against P. aeruginosa isolated from patients with mucoviscidosis].
    Croize J; Gout JP; Robert J; Le Noc P
    Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):573-7. PubMed ID: 2508041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Collateral sensitivity between aminoglycosides and beta-lactam antibiotics depends on active proton pumps.
    Azimi L; Rastegar Lari A
    Microb Pathog; 2017 Nov; 112():122-125. PubMed ID: 28958949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vitro combination effects of astromicin and beta-lactam antibiotics against Pseudomonas aeruginosa. In vitro synergistic activities].
    Iyama Y; Sato K; Okachi R
    Jpn J Antibiot; 1985 Apr; 38(4):1022-8. PubMed ID: 3928940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotypic and phenotypic analyses of a Pseudomonas aeruginosa chronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strains.
    Varga JJ; Barbier M; Mulet X; Bielecki P; Bartell JA; Owings JP; Martinez-Ramos I; Hittle LE; Davis MR; Damron FH; Liechti GW; Puchałka J; dos Santos VA; Ernst RK; Papin JA; Albertí S; Oliver A; Goldberg JB
    BMC Genomics; 2015 Oct; 16():883. PubMed ID: 26519161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of antibiotic susceptibility patterns in Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) with invasive Pseudomonas aeruginosa from non-CF patients.
    Rao P; McCaughan J; McCalmont M; Goldsmith CE; Hall V; Millar BC; McCann MA; Downey DG; Rendall JC; Elborn JS; Moore JE
    J Cyst Fibros; 2012 Jul; 11(4):349-52. PubMed ID: 22325689
    [No Abstract]   [Full Text] [Related]  

  • 16. Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms.
    Bosso JA; Mauldin PD; Steed LL
    Ann Pharmacother; 2006 Nov; 40(11):1946-9. PubMed ID: 17018687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis.
    Mathy V; Grohs P; Compain F
    J Med Microbiol; 2018 Sep; 67(9):1217-1220. PubMed ID: 30016231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel approach to the eradication of Pseudomonas aeruginosa in an infant with CF after outpatient treatment failure.
    Hayes D; Kanga JF; Anstead MI; Kuhn RJ
    Pediatr Pulmonol; 2008 May; 43(5):511-3. PubMed ID: 18383117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection.
    Moskowitz SM; Foster JM; Emerson JC; Gibson RL; Burns JL
    J Antimicrob Chemother; 2005 Nov; 56(5):879-86. PubMed ID: 16188918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of the Pseudomonas aeruginosa Aminoglycoside Mutational Resistome
    López-Causapé C; Rubio R; Cabot G; Oliver A
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.